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Tanshinone IIA (Tan IIA) and sodium tanshinone IIA sulfonate (STS) were found to have protective eﬀects on cardiomyocyte
against adriamycin-induced damage and may be used clinically. It is unclear whether the supplementation of STS or Tan IIA
would aﬀect the anticancer activity of anthracycline. To evaluate the eﬀect of Tan IIA or STS on the anticancer of epirubicin,
the cell viability, apoptosis, Akt expression, and uptake of epirubicin after supplementation of Tan IIA or STS in the epirubicin-
treated BT-20 cells were measured and compared. Tan IIA inhibited BT-20 cell growth and induced apoptosis in a time- and
dose-dependent manner. When Tan IIA was used with epirubicin, an increase of BT-20 cells apoptosis was accompanied by the
decreasing phosphorylation of Akt. STS had no eﬀect on the cell viability of BT-20 cells. However, when used with epirubicin, STS
decreased the epirubicin-induced cytotoxicity and apoptosis in BT-20 cells. The antagonistic eﬀect of STS on epirubicin-induced
cytotoxicity in BT-20 cells occurred concomitantly with the reduced epirubicin uptake and the increased phosphorylation of Akt.
STS decreased the uptake of epirubicin in BT-20 cells and blocked epirubicin-induced apoptosis through activation of Akt.
1.Introduction
Breast cancer is one of the leading causes of cancer death
among women all over the world; it accounts for approx-
imately 30% of all new cancer cases each year, with an
annual incidence of approximately 200,000 in the United
States [1]. In Taiwan, the incidence of breast cancer has
increased steadily from 10/105 in 1979 to 50/105 in 2006, and
it is now the most commonly occurring cancer and leading
cause of death among Taiwanese women [2]. Anthracyclines
such as doxorubicin and epirubicin are highly eﬃcacious
againstbreastcancer[3],andar ec ommonlyus edinadju vant
or neoadjuvant chemotherapy to reduce local recurrence or
distant metastasis [4, 5]. However, their widespread use was
limited by their cardiotoxicity, which was irreversible and
cumulatively dose related [6–12].
Danshen, a traditional Chinese medicine derived from
the dry root or rhizome of Salviae miltiorrhizae Bge,
is widely used in China and other countries, including
the United States [13, 14]. The reported cardioprotective
eﬀects of Danshen include improving microcirculation [15],
suppressing the formation of thromboxane [16], inhibiting
platelet adhesion and aggregation [17], and protecting
against myocardial ischemia [13], as well as its angiotensin
II-induced hypertrophic response [18, 19]. Among the more
than 30 diterpene compounds, tanshinone IIA (Tan IIA),
a lipid-soluble compound, and sodium tanshinone IIA
sulfonate (STS), the water-soluble derivative of tanshinone
IIA,are the two most well-knownandabundantcomponents
of Danshen [13, 20, 21].
The exact mechanisms of anthracycline-related car-
diotoxicityarenotfullyunderstood,butithasbeensuggested2 Evidence-Based Complementary and Alternative Medicine
thatoxidativestress, oxygen-free radicals, iron chelation, and
lipid peroxidation may play important roles [7, 12, 22]. Tan
IIA and STS were reported to have antioxidant properties,
which could break the chain reactions of peroxidation by
scavenging lipid-free radicals [20], and increase the activity
of superoxide dismutase (SOD) [23]. Recent studies have
revealed that Tan IIA [24, 25]a n dS T S[ 26, 27]h a v et h ep r o -
tective eﬀects of cardiomyocyte against adriamycin-induced
lipidperoxidationand oxidativestress-mediated apoptosis in
preclinical experiments. The cardioprotective eﬀect of Tan
IIA and STS against adriamycin-related cardiotoxicity might
be a potential therapeutic agent for clinical use.
For a cardioprotective agent to be used clinically, it is
important to conﬁrm that it will not impair the anticancer
eﬀect of chemotherapy [28]. At present, it is unclear
whether the supplementation of STS or Tan IIA would aﬀect
the anticancer eﬀect of anthracyclines, such as epirubicin.
Therefore, the objective of this in vitro study was to elucidate
the inﬂuence of STS or Tan IIA on the epirubicin-induced
cytotoxicity of breast cancer cells.
2.Materialsand Methods
2.1. Cell Lines and Culture. The human breast cancer cell
line BT-20 was obtained from the American Type Culture
Collection (ATCC). BT-20 breast cancer cells were main-
tained at 37◦Ci n5 %C O 2 and 95% air and grown in
RPMI 1640 medium supplemented with 10% fetal bovine
serum, 100IU/mL penicillin, and 100mg/mL streptomycin
(Invitrogen, Carlsbad, CA).
2.2. Compounds. STS and Tan IIA purchased from Herbasin
Co., Ltd. (Shenyang, China) were dissolved in PBS and
DMSO separately, at 2mg/mL and 5mg/mL, and used as
stock.Epirubicin150mg/vialwaspurchasedfromPharmacia
& Upjohn S.P.A. (Milan, Italy) and dissolved in PBS at
30mg/mL as stock.
2.3. Cell Viability Assay. Cell viability was evaluated by the
WST-1 assay (BioVision, Mountain View, CA). The WST-1
assay measures the activity of mitochondrial dehydrogenases
of viable cells by reducing tetrazolium salt to formazan.
Brieﬂy, cells (1 × 104/well) were seeded in 96-well plates
overnight, followed by epirubicin and/or STS (or Tan IIA)
treatment for72hours. Then, WST-1was addedtoeachwell,
a n dt h ec e l l sw e r ei n c u b a t e da t3 7 ◦C for 4 hours. Finally,
plates were measured at OD450 and referenced at OD620
with a microplate reader (SunriseTM, Tecan Groug LTD,
Austria). At least three wells per group were analyzed, and
the procedure was repeated three times.
2.4. Apoptosis Analyses. BT-20 cells were plated in 12-well
plates (6 × 105/well) and incubated with STS or Tan IIA
at diﬀerent concentrations for 48–72 hours. The cells were
then harvested by centrifugation, ﬁxed with 70% ethanol (in
PBS) at 4◦C overnight, and resuspended in PBS containing
4μg/mL of propidium iodide (PI) (Sigma), 0.1mg/mL
RNase A, and 0.1% Triton X-100 in the dark. The cell
suspension was incubated at 37◦Cf o r3 0m i n u t e s .T h ec e l l
cycle was determined and analyzed with ﬂow cytometry
(Beckman Coulter, USA) equipped with an argon ion laser
at a 488nm wavelength.
2.5. Determination of Epirubicin Uptake. Epirubicin 1μg/mL
was used for the measurement of uptake of BT-20 cells by
ﬂow cytometer (Becton Dickinson FACScan), using laser
emitting at 488nm, close to the absorption maximum of
epirubicin [29]. BT-20 cells were plated in 12-well plates
(9∗104/well) and incubated with epirubicin 1μg/mL and/or
STS (or Tan IIA) treated with diﬀerent concentrations for
24 hours. The cells were then harvested by centrifugation
and ﬁxed with 4% paraformaidehyde at 4◦Co v e r n i g h t ,i n
thedark. The ﬂuorescenceintensity increased paralleled with
the uptake of epirubicin into BT-20 cells and was used to
determine the cell uptake of epirubicin.
2.6. Determination of Combinatorial Eﬀects. The ability of
STS (or Tan IIA) and epirubicin to act in a synergistic,
additive, or antagonistic manner with regard to growth
inhibition was determined by a combination index (CI) as
proposed by Chou and Talalay [30, 31]. Calcusyn software
(Biosoft, Great Shelford, Cambridge, UK) was used to
determine the CI for each concentration of drug mixture
used. AvalueofCI<1represents a casein which asynergism
of epirubicin and STS (or Tan IIA) was present. CI values
of 1 and >1 represent additive and antagonistic eﬀects,
respectively.
2.7. AktActivationin thePresence orAbsenceof Tan IIA orSTS
inEpirubicin-Treated BT-20BreastCancer Cells. Constitutive
Akt signaling appears to play an important role in the pro-
liferative activity, resistance to chemotherapy, and hormone
therapy of breast cancer cells [32–34]. We further surveyed
whether an Akt-related pathway was involved in the anti-
apoptotic eﬀect conferred by STS (or Tan IIA) in epirubicin-
treated breast cancercells. After drug treatment for 24 hours,
cells were harvested and lysed with the lysis buﬀer (20mM
Tris pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1%
Triton X-100, 2.5mM sodium pyrophosphate, 1mM glyc-
erolphosphate, 1mM Na3VO4, 1mM phenylmethylsulfonyl
ﬂuoride, 10mg/mL leupeptinand 10mg/mL aprotinin). The
lysates were quantiﬁed by Bradford assay and heated at
95◦C for 5 minutes in a sample buﬀer. Fifty micrograms
of protein were separated by 8% polyacrylamide gels and
transferred to PVDF membranes (Millipore, Bedford, MA).
The membranes were blocked for one hour with 5% nonfat
dried milk in 0.1% PBST (500mL 1X PBS with 0.5mL
Tween-20) at room temperature, and then were incu-
bated with Akt, phosphorylated Akt (phospho-Akt), JNK,
phosphorylated JNK (phospho-JNK), p38, phosphorylated
p38 (phospho-p38), MAPK, and phosphorylated MAPK
(phospho-MAPK) speciﬁc primary antibodies overnight
at 4◦C. Later, membranes were washed three times with
PBST and incubated with horseradish peroxidase- (HRP-)
conjugated secondary antibody for one hour at room
temperature. Afterwashing with PBSthreetimes, theproteinEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀect ofTanIIA orSTS onthe growthofBT-20breast cancer cells. (a)BT-20cells were treated with2,10,25,and50μg/mL of Tan
IIA or STS for 72h. The cell growth was determined by WST-1 assay. (b) BT-20 cells were treated with 2, 10, 25, and 50μg/mL of Tan IIA or
STS for 24h or 48h. The ratio of apoptosis was determined by ﬂow cytometry. Data are the mean ± SD of triplicates from a representative
assayof three separate experiments.
signals were detected by an enhanced chemiluminescence
(ECL) detection system (Amersham Biosciences, Piscataway,
NJ). The band densities were quantiﬁed by using Image
Js o f t w a r e( http://rsb.info.nih.gov/ij/) and normalized the
ratio of phospho-AKT/total-AKT, phospho-JNK/total-JNK,
phospho-p38/total p38, and phospho-MAPK/MAPK to β-
actin for protein loading.
Antibody for Akt, phospho- A k t ,J N K ,p h o s p h o - J N K ,
p38, phospho-p38, MAPK, and phospho-MAPK were pur-
chased from Cell Signaling TECHNOLOGY. HRP-conjuga-
ted goat antimouse and mouse antirabbit IgG antibod-
ies were obtained from Amersham (Freiburg, Germany).
Rhodamine-conjugated rabbitantimouse was obtained from
JacksonLaboratory (WestGrove,WI).Anti-β-actin antibody
was obtained from Sigma (St. Louis, MO). Other materials
and reagents not speciﬁed were obtained from Sigma or
Merck.
2.8. Statistical Analyses. Analyses were performed using the
Statistics Analysis System (SAS 9.1). Data are presented as
mean ±standard deviationexceptwhere indicated.Compar-
isonsbetweengroupswereanalyzedusingthechi-squaretest,
Student’s two-tailed t test, or one-way analysis of variance
(ANOVA) with Bonferroni’s correction as appropriate. A
value of P<. 05 was considered statistically signiﬁcant.
3.Results
3.1. Eﬀect of STS or Tan IIA on Growth of BT-20 Breast
Cancer Cells. To evaluate the eﬀect of STS or Tan IIA on
breast cancer cells in vitro, BT-20 breast cancer cells were
exposed to 2–50μg/mL of Tan IIA or STS for 72 hours. The
cell viability was determined by WST-1 assay. As shown in
Figure 1(a), after treatment with 2–50μg/mL of Tan IIA, the
growthofBT-20cellsdecreasedinadose-dependentmanner.
I nc o n t r a s t ,S T Sh a dn os i g n i ﬁ c a n te ﬀect on the growth of
BT-20 breast cancer cells.
3.2. Apoptotic Eﬀect of STS or Tan IIA on BT-20 Breast Cancer
Cells. In the cell cycle analysis, treatment of BT-20 cells with
1a n d1 0μg/mL of Tan IIA did not result in any signiﬁcant
apoptosis, while treatment of BT-20 cells with 50μg/mL Tan
IIA resulted in a 70% increase of apoptosis at 48 hours
as compared with the control (Figure 1(b)). No apparent
apoptosis was found with STS, even at concentrations of
50μg/mL.
3.3. Supplementation of STS (or Tan IIA) in Epirubicin-
Treated BT-20 Breast Cancer Cells. The BT-20 breast cancer
cell line used here was sensitive to epirubicin in a dose-
dependent manner. When the concentration of epirubicin
reached 2μg/mL, almost all the BT-20 breast cancer cells
were nonviable (Figure 2(a)). Supplementation with STS
increased the cell viability of BT-20 cells under epirubicin
treatment, while Tan IIA potentiated the cytotoxicity of
epirubicin on BT-20 cells.
The addition of 50μg/mL STS and 25μg/mL Tan
IIA to 1μg/mL epirubicin-treated BT-20 cells decreased
epirubicin-induced apoptosis (Figure 2(b)). The combina-
tion of 50μg/mL Tan IIA and 1μg/mL epirubicin resulted in
higher apoptosis in BT-20 cells than epirubicin alone.
The combination eﬀect of epirubicin with STS (or Tan
IIA) on BT-20 cells was analyzed with Calcusyn. The com-
bination of epirubicin with STS, most of the time, exerted4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀect of Tan IIA or STS on epirubicin-induced cytotoxicity and apoptosis in BT-20 breast cancer cells. (a) BT-20 breast cancer
cells were treated with 0–2μg/mL epirubicin in the presence or absence of STS (0–50μg/mL) or Tan IIA (0–50μg/mL) for 72h. The cell
growth was determined by WST-1 assay. (b) BT-20 cells were treated with 1μg/mL of epirubicin. The change in apoptosis with the addition
of STS (50μg/mL) and Tan IIA (2, 10, 25, 50μg/mL) in epirubicin- (Epi-) treated BT-20 cells was determined by ﬂow cytometry at 48 or
72h. ∗P<. 05 when compared with the control group; +P<. 05 when compared with the epirubicin group. Data are the mean ± SD of
triplicates from a representative assay of three separate experiments.
an antagonistic eﬀect. While combination of epirubicin with
Tan IIA resulted in a more complex synergistic, additive or
antagonistic eﬀect at diﬀerent drug concentration combina-
tions (Table 1).
3.4. Uptake of Epirubicin in BT-20 Cells in the Presence or
AbsenceofSTS orTan IIA. Wethendetermined theuptakeof
epirubicininBT-20 cellsbeforeand aftersupplementationof
S T So rT a nI I A ,u s i n gﬂ o wc y t o m e t r y .W h e nc o t r e a t e dw i t h
STS, the uptake of epirubicin in BT-20 breast cancer cells
was decreased in a dose-dependent manner (Figure 3(a)). In
contrast, Tan IIA dose-dependently increased the uptake of
epirubicin in BT-20 breast cancer cells (Figure 3(b)).
3.5. Activation of the Akt-Related Pathway with the Supple-
mentation of STS (or Tan IIA) in Epirubicin-Treated BT-
20 Breast Cancer Cells. The expression of Akt, phospho-
Akt, JNK, phospho-JNK, p38, phospho-p38, MAPK, and
phospho-MAPK with the supplementation of STS or Tan
IIA to epirubicin-treated BT-20 breast cancer cells was
evaluated by Western blot. When STS was added, the level
of phospho-Akt was increased along with the increase of
dose (Figure 4(a)). In contrast, Tan IIA treatment of BT-
20 cells resulted in a decreased expression of phospho-Akt
in a dose-dependent manner (Figure 4(b)). The activation
of Akt in epirubicin-treated BT-20 breast cancer cells was
found in the STS + epirubicin group, but not in the Tan
IIA+epirubicingroup.ThephosphorylatedMAPK,JNK,and
p38 were slightly increased in the treatment of BT-20 cells
withSTS,orepirubicincombinedwithSTS.Onthecontrary,
the phosphorylation of MAPK, JNK, and p38 were slightly
d e c r e a s e di nB T - 2 0c e l l sw h e nt r e a t e dw i t hT a nI I A ,o rt h e
combination of Tan IIA with epirubicin.
4.Discussion
Our study was designed to test the eﬀect of supplementation
of STS or Tan IIA on the anticancer eﬀect of epirubicin in an
in vitro BT-20 cell line model. In our study, STS alone had
no eﬀect on growth inhibition or apoptosis in BT-20 breast
cancer cells, while Tan IIA could dose-dependently reduce
BT-20 breast cancer cell viability and induce apoptosis.
The supplementation of STS to epirubicin-treated BT-20
cells reduced epirubicin-related cytotoxicity and apoptosis.
The supplementation of Tan IIA to epirubicin-treated BT-
20 breast cancer cells potentiated the cytotoxic eﬀect of
epirubicin. The antagonistic eﬀect of STS on epirubicin-
induced cytotoxicity in BT-20 breast cancer cells occurred
concomitantly with the reduced uptake of epirubicin and
increased phosphorylation of Akt.
Epirubicin,a commonly used chemotherapeuticagent in
adjuvant or neoadjuvant settings to reduce local recurrence
ordistantmetastasis [4,5],ishighly eﬃcaciousagainst breast
cancer; a concentration of epirubicin as low as 0.2μg/mL
could reduce BT-20 breast cancer cell growth by 50%.
Tan IIA, the lipophilic extract of Danshen, had a growth-
inhibiting eﬀect on BT-20 breast cancer cells and induced
apoptosis in a dose-dependent manner. The anticancer
eﬀect of Tan IIA has been reported in acute promyelocytic
leukemia [35], human glioma cells [36], breast cancer cells
[37], hepatoma cells [38], and vascular endothelial cells
[39]. STS, the water soluble form of Tan IIA, did not haveEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Uptake of epirubicin in BT-20 breast cancer cells in the presence or absence of STS (a) or Tan IIA (b) treatment for 24h. Data are
themean ±SDoftriplicates fromarepresentative assayofthreeseparateexperiments. ∗P<. 05ascomparedwith1μg/mLepirubicin-treated
BT-20 cells.
a growth inhibitory eﬀect, nor did it induce apoptosis, even
at a 50μg/mL concentration.
The inﬂuence of the supplementation of STS or Tan
IIA on the anticancer eﬀect of epirubicin was unclear. In
our in vitro cell line study, the supplementation of STS
to epirubicin-treated BT-20 cells reduced the cell growth
inhibitoryeﬀectofepirubicinandinterferedwithepirubicin-
induced apoptosis. The supplementation of Tan IIA to
epirubicin-treated BT-20 breast cancer cells potentiated
the cytotoxic eﬀect of epirubicin (Figure 2(a)). Although
a decrease of epirubicin-related apoptosis was found when
Tan IIA (25μg/mL) was used with epirubicin (Figure 2(b)),
the overall cell viability was decreased. This discrepancy
might be related to cell death other than apoptosis, like an
increase of necrosis, autophage [40], or cell cycle arrest.
The interaction of STS or Tan IIA with epirubicin
was further evaluated by the Calcusyn software, which is
commonly used for the analysis of drug combination eﬀect.
STS when used with epirubicin had an antagonistic eﬀect,
whileinteractionofTanIIAwithepirubicinismorecomplex.6 Evidence-Based Complementary and Alternative Medicine
Table 1: Interaction between STS (or Tan IIA) and epirubicin on the growth of BT-20 breast cancer cells.
Epirubicin (μg/mL) STS (μg/mL) Tan IIA (μg/mL) Fa CI Eﬀect
0.03125 25 0.048 2.014 Antagonistic
0.0625 25 0.0313 3.931 Antagonistic
0.125 25 0.0686 3.314 Antagonistic
0.25 25 0.0869 4.713 Antagonistic
0.5 25 0.1447 5.626 Antagonistic
1 25 0.2323 6.95 Antagonistic
2 25 0.7902 2.038 Antagonistic
0.03125 50 0.0492 3.166 Antagonistic
0.0625 50 0.0351 5.15 Antagonistic
0.125 50 0.0776 3.825 Antagonistic
0.25 50 0.0683 6.652 Antagonistic
0.5 50 0.2 4.557 Antagonistic
1 50 0.423 3.733 Antagonistic
2 50 0.8946 1.131 Additive/antagonistic
0.03125 25 0.6109 1.066 Additive/antagonistic
0.0625 25 0.5097 1.302 Additive/antagonistic
0.125 25 0.6354 1.197 Additive/antagonistic
0.25 25 0.8371 0.902 Synergistic
0.5 25 0.8257 1.141 Additive/antagonistic
1 25 0.8341 1.511 Antagonistic
2 25 0.8926 1.708 Antagonistic
0.03125 50 0.9412 1.013 Additive/antagonistic
0.0625 50 0.9422 1.018 Additive/antagonistic
0.125 50 0.9392 1.057 Additive/antagonistic
0.25 50 0.9382 1.106 Additive/antagonistic
0.5 50 0.9366 1.205 Additive/antagonistic
1 50 0.9372 1.377 Antagonistic
2 50 0.9374 1.728 Antagonistic
Fa: fraction aﬀected; CI: combination index.
Av a l u eo fC I<1 represents a case where synergism of epirubicin and STS (or Tan IIA) was present. CI values of 1 and >1 represent additive and antagonistic
eﬀects, respectively.
In most circumstances, STS when used with epirubicin
would result in an antagonistic eﬀect. When Tan IIA was
used with epirubicin, most of the time there would be
an additive eﬀect. The synergistic eﬀect was found when
0.25μg/mL epirubicin was used with 25μg/mL Tan IIA.
However, an antagonistic eﬀect was present when high
concentration (≥1μg/mL) of epirubicin was used with Tan
IIA. The antagonistic eﬀect of STS on chemotherapy-related
cytotoxicity in breast cancer cells is rarely reported. Since an
antagonistic eﬀect between drugs would cause a suboptimal
therapeutic eﬀect, it is important that combining epirubicin
with STS should be avoided.
A drug’s successful entrance into cells is the ﬁrst step in
the eradication of malignant cancer cells. Failure of a drug to
pump into cells, or the ability of cancercells to actively eﬄux
drugs, leads to a decrease in cellular drug accumulation to a
subtoxic level and is frequently related to the development
of drug resistance [41, 42]. We used ﬂow cytometry to
determine the uptake of epirubicin in BT-20 cells before and
after supplementation of STS or Tan IIA. When cotreated
with STS, the uptake of epirubicin in BT-20 breast cancer
cells was decreased in a dose-dependent manner. In contrast,
Tan IIA dose-dependently increased the uptake of epirubicin
in BT-20 breast cancer cells. These ﬁndings were compatible
with the observation that the supplementation of STS will
interfere with the epirubicin-related anticancer eﬀect, while
the combination of Tan IIA with epirubicin would potential
the cytotoxic eﬀects of epirubicin.
Constitutive Akt signaling plays an important role in cell
proliferation and resistance to hormone or chemotherapy in
breast cancer [32–34]. The STS dose-dependently increased
the phosphorylation of Akt in BT-20 breast cancer cells. In
the epirubicin-treated BT-20 cells, the supplementation of
STS also dose-dependently increased the phosphorylation
of Akt. The upregulation of Akt renders BT-20 cells more
resistant to epirubicin-related cytotoxicity. This could partlyEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Akt-related pathway activation in the presence or absence of STS (or Tan IIA) in epirubicin-treated BT-20 breast cancer cells for
24h. (a) Representative results of Western blotting showing changes in the levels of Akt, phospho-Akt, JNK, phospho-JNK, P38, phospho-
p38, MAPK, and phospho-MAPK in BT-20 cells treated with STS and/or 1μg/mL epirubicin. (b) Representative results of Western blotting
showing changes in the levels of Akt, phospho-Akt, JNK, phospho-JNK, P38, phospho-p38, MAPK, and phospho-MAPK in BT-20 cells
treated with Tan IIA and/or 1μg/mL epirubicin.
explain the antagonistic eﬀect of STS when combined with
epirubicin. On the other hand, Akt phosphorylation in BT-
20 breast cancer cells was decreased after supplementation
with Tan IIA. This was consistent with the additive and
synergistic cytotoxic eﬀect of Tan IIA and epirubicin in BT-
20 breast cancer cells.
STS may be an active cardioprotectant, as revealed in
previous reports [19, 20, 23, 26, 27], although none of them
discussed the interaction between STS and epirubicin. Our
preclinical result showed that STS may interfere with the
anticancer eﬀect of epirubicin. The decrease in epirubicin-
induced BT-20 breast cancer cell cytotoxicity after supple-
mentation with STS may be due to the decreased uptake of
epirubicin and the activation of Akt. One possibility is that
STS had a similar eﬀect on cardiomyocytes in blocking the
uptake of epirubicin and activating the Akt pathway. If this
is the case, then STS may not be an ideal cardioprotectant
in patients undergoing chemotherapy with anthracycline.
The cardioprotective [24, 25] and anticancer [35–39]e ﬀects
of Tan IIA, without disturbing the anticancer eﬀect of
epirubicin, supported the possible role of Tan IIA as a
cardioprotectant. However, our study was limited, in that
we did not perform an in vivo study to further conﬁrm the
eﬀects of STS and Tan IIA observed in the in vitro breast
cancer cell line.
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